AZD0120

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Autoimmune Cytopenia Elimination by Chimeric Antigen Receptor T-cell Therapy

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

A Study of AZD0120 in Autoimmune Diseases

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants